Covaxin Phase 3 clinical trial shows 81% efficacy

India’s first indigenously produced Covid-19 vaccine has been developed jointly by the ICMR and Bharat Biotech

geetanjali

Geetanjali Minhas | March 4, 2021 | Mumbai


#healthcare   #Novel Coronavirus   #Covid-19   #vaccination   #Covaxin   #ICMR   #bharat Biotech   #DGCI  


India’s first indigenously produced Covid-19 vaccine, Covaxin, has shown an interim efficacy of 81% in Phase III trials for preventing the virus. Covaxin has been developed in India jointly by the Indian Council of Medical Research (ICMR) along with Bharat Biotech International Limited (BBIL).        

The Phase III trial was initiated by ICMR and BBIL in mid-November 2020 and it was conducted on a total of 25,800 individuals across 21 sites. The interim efficacy of 81%, analyzed as per the protocol approved by the Drugs Controller General of India (DCGI), puts it at par with other global front-runner vaccines.

The initial interim analysis of Phase III trial data is based on 43 cases of Covid-19 of which 36 cases of Covid-19 were observed in the placebo group and 7 cases observed in the Covaxin group resulting in a point estimate of vaccine efficacy of 80.6 percent.

Bharat Biotech expects to get a clearer picture of its efficacy once 130 cases are accumulated among its participants. Phase 1 and Phase 2 clinical trials were conducted on 755 participants and demonstrated high safety profile of the candidate vaccine with seroconversion rates of 98.3% and 81.1% on day 56 and 104 respectively.

The results have been evaluated by an independent data safety and monitoring board show that the vaccine is well-tolerated and efficacious against SARS-CoV-2 across a wide range of age groups and variants in the country.

In March 2020, following the successful isolation of the SARS CoV-2 virus at ICMR-National Institute of Virology (NIV), ICMR entered into a public-private partnership with BBIL to develop the virus isolate into an effective vaccine candidate. ICMR-NIV characterized the vaccine developed by BBIL through in-vitro experiments and electron microscopy studies. Pre-clinical studies in small animals and hamsters showed promising results for safety and immunogenicity. Further studies conducted in rhesus macaques also established remarkable safety and protective efficacy of Covaxin.

“Covaxin has been developed on WHO prequalified vero cell platform globally recognized with a well-established track record of safety. Covaxin’s ability to neutralize UK variant strain of SARS-CoV-2 has also recently been established,” the ICMR said in its statement.

“The bench-to-bedside journey of completely indigenous Covid-19 vaccine in less than 8 months’ time showcases immense strength of Atmanirbhar Bharat [self-reliant India] to fight the odds and stand tall in the global public health community. It is also a testament to India’s emergence as a global vaccine superpower,” said Dr. Balram Bhargava, director general, ICMR.

“Covaxin demonstrated 81 percent interim efficacy in preventing Covid-19 in those without prior infection after the second dose. Data from 25,800 participants who received a vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated,” BBL said in its statement.

According to the Hyderabad-based vaccine maker, inclusion of the Algel-IMDG adjuvant in the vaccine enhances T-cell immune responses to Covid-19 leading to long-term protection. The vaccine has been approved for restricted emergency use under clinical trial mode and will have to be taken in two doses 28 days apart.

“With today’s results from our Phase 3 trials we have now reported data on our Covid-19 vaccine from Phase 1, 2 and 3 trials involving around 27,000 participants. Covaxin also demonstrates significant immunogenicity against the rapidly emerging variants,” said Dr Krishna Ella, chairman and manging director, Bharat Biotech.

Covaxin Timeline:
March 11, 2020: Covid-19 was declared a pandemic by the WHO. India joined the global race of developing safe and effective vaccines to protect its citizens as well as the global community from this dreaded disease.
• March 13, 2020: ICMR-National Institute of Virology (ICMR-NIV) successfully isolates the SARSCoV-2 virus. India becomes the 5th country in the world to achieve this feat.
• April 2020: ICMR enters into a public-private partnership with Bharat Biotech International Ltd (BBIL) for developing an effective vaccine candidate for SARS-CoV-2.
• May 2020: ICMR-NIV transfers the virus strain to BBIL and characterizes the vaccine developed by BBIL through in-vitro experiments and electron microscopy studies.
• June-August 2020: Experiments in small animals (mouse, rats and rabbits) and hamsters established promising safety and immunogenicity of COVAXIN. Data has been published by the highly reputed journal of the Cell Press.
• July-August 2020: Studies conducted in rhesus macaques established safety and protective efficacy of Covaxin. Results established the remarkable ability of the vaccine candidate to clear the virus from infected organs along with its capacity to mount B and T cell immune response.
• July-October 2020: Phase 1 and 2 clinical trials conducted in 755 participants demonstrated a high safety profile of the candidate vaccine along with seroconversion rates of 98.3% and 81.1% respectively on day 56 and 104 respectively. The results are published in Lancet's journal.
• November 2020: The largest ever clinical trial for COVID-19 in India launched for the third phase with over 25,800 participants
• January 3, 2021: DCGI grants approval for restricted use in emergency situations for COVAXIN
• January 16, 2021: India rolls-out phase-wise COVID-19 vaccine administration starting with healthcare and frontline workers
• January 27, 2021: COVAXIN’s ability to neutralize UK variant strain of SARS-CoV-2 established and published in Journal of Travel Medicine.
• March 3, 2021: Interim results of Phase 3 efficacy trials of COVAXIN show 81% efficacy against SARS-CoV-2virus. The follow-up of participants in the trial are still ongoing.


 

Comments

 

Other News

HPCL, Tata Steel among National CSR Award 2020 winners

Hindustan Petroleum Corporation, HDFC, Tata Steel and Tech Mahindra are among the winners and the recipients of honourable mentions in the National CSR Awards 2020 announced by the ministry of corporate affairs (MCA) on Thursday. The MCA instituted the annual National Corporate Social Respon

India’s tree lovers get together for a nation-wide tree festival

A good monsoon has left the trees all washed and spruced up. It’s right time to take a good look at them, and also to tell the young generation about their diversity. So, tree lovers across the country have joined hands to celebrate a festival of trees this month. The August Tree Fest

How did a policeman move unarmed and fearlessly for 37 long years in Bihar?

Unbounded: My Experiments with Law, Physics, Policing and Super 30 By Abhayanand Rupa Publications, 344 pages, Rs 595   Abhayanand has

India@75: A timely study of the state of the nation

India after 1947: Reflections & Recollections By Rajmohan Gandhi Aleph, 118 pages, Rs 399 Rajmohan Gandhi was about 11 when India won independence. As the nation celebrates 75 years of freedom, how would he – and others like him – feel?

BMC denies protocol breach in ‘Har Ghar Tiranga’

The BrihanMumbai municipal corporation (BMC) has rebutted a Shiv Sena leader’s allegation of breach of protocol in the implementation of the ‘Har Ghar Tiranga’ campaign. On Friday Rahul Shewale, group leader of Shiv Sena in Lok Sabha, had accused BMC commissioner IS Chahal

Mumbai`s stalled building projects: Is self-redevelopment the real solution?

Land in Mumbai city, which is surrounded by water on three sides, is scarce and has a premium. Property prices in certain areas of financial capital of the country are as much as Rs 1 lakh per sq ft. Yet, 5,800 buildings have been lying in a stalled condition for the last 18 years. Meanwhile

Visionary Talk: Amitabh Gupta, Pune Police Commissioner with Kailashnath Adhikari, MD, Governance Now


Archives

Current Issue

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter